Cover Image
市場調查報告書

癲癇治療藥的全球市場:2016-2020年

Global Epilepsy Drugs Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 363152
出版日期 內容資訊 英文 87 Pages
訂單完成後即時交付
價格
Back to Top
癲癇治療藥的全球市場:2016-2020年 Global Epilepsy Drugs Market 2016-2020
出版日期: 2016年07月05日 內容資訊: 英文 87 Pages
簡介

癲癇,是起因於腦內的抑制性、興奮性信號間的平衡以異常反復發作為特徵的疾病。癲癇症狀也因腦的形成異常和腫瘤,生產時的外傷,高風險妊娠所引起,有的無害,也有的有生命威脅,不過,大多病因未明。癲癇治療藥的全球市場,預計今後數年的年複合成長率為4.45%。

本報告以癲癇治療藥的全球市場為焦點,提供2016-2020年期間其變遷的各藥物世代,活性頻譜,發病形式及地區(南北美洲,亞太地區,歐洲、中東、非洲)的分析、預測,未來的發展樣貌,預測,主要加入企業簡介等的最新資訊。

第1章 摘要整理

  • 焦點

第2章 報告的範圍

  • 市場概要
  • 主要企業的銷售產品

第3章 市場調查方法

  • 取材方式
  • 經濟指標

第4章 簡介

  • 主要市場焦點
  • 癲癇 - 概要

第5章 開發平台分析

第6章 抗癲癇藥的重要購買標準

第7章 市場環境

  • 市場概要
  • 波特的五力分析

第8章 癲癇治療藥的全球市場:各藥物世代

  • 第一世代抗癲癇藥
  • 第二世代抗癲癇藥
  • 第三代抗癲癇藥

第9章 癲癇治療藥的全球市場:各活性頻譜

  • 狹頻譜抗癲癇藥
  • 廣頻譜抗癲癇藥

第10章 癲癇治療藥的全球市場:各發病形式

  • 部分性發作起始
  • 般性發作

第11章 癲癇治療藥的全球市場:各地區

  • 癲癇治療藥的全球市場 - 各地區:2016-2020年
  • 南北美洲的癲癇治療藥市場
  • 美國的癲癇治療藥市場
  • 歐洲、中東、非洲的癲癇治療藥市場
  • 亞太地區的癲癇治療藥市場
  • 日本的癲癇治療藥市場
  • 澳洲的癲癇治療藥市場
  • 中國的癲癇治療藥市場
  • 印度的癲癇治療藥市場

第12章 癲癇治療藥的全球市場:推動要素

  • 後期開發平台分子的暫定核准
  • 特別規定
  • 使用嶄新的技術的新療法的開發

第13章 推動要素的影響度

第14章 癲癇治療藥的全球市場:課題

  • 圍繞癲癇的社會烙印
  • 發作管理設備的利用擴大成為開發新藥的威脅
  • 開發新藥企業的獎勵、投資的遞減

第15章 推動要素及課題的影響度

第16章 癲癇治療藥的全球市場:趨勢

  • 發作偵測和藥物治療追蹤的設備及智慧型手機應用程式的開發
  • 成藥的改性
  • 新世代藥物的採用擴大

第17章 商業環境

  • 競爭情形
  • 重要新聞

第18章 主要供給企業分析

  • Eisai株式會社
  • GSK
  • Pfizer
  • UCB
  • 其他主要企業

第19章 附錄

  • 簡稱一覽

第20章 關於Technavio

目錄
Product Code: IRTNTR8891

About the Epilepsy Drugs Market

Epilepsy is characterized by recurrent seizures caused by the improper balance between inhibitory and excitatory signals in the brain. The symptoms of epilepsy, caused by brain malformations and tumors, birth trauma, and high-risk pregnancies, can be benign or life-threatening. A majority of epilepsy cases have an unknown etiology.

Etiology

Etiology varies according to the age of a person. Some individuals genetically inherit the disease while the cause of the disease in others is unknown. Head injuries, tumors, autism spectrum disorder, or stroke can also cause the disorder.

Technavio's analysts forecast the global epilepsy drugs market to grow at a CAGR of 4.45% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global epilepsy drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent epilepsy and related seizures. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Epilepsy Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Eisai
  • GSK
  • Pfizer
  • UCB

Other Prominent Vendors

  • AbbVie
  • Acorda Therapeutics
  • Alexza Pharmaceuticals
  • Aprecia Pharmaceuticals
  • Aurobindo Pharma
  • Biscayne Pharmaceuticals
  • CURx Pharmaceuticals
  • Dainippon Sumitomo Pharma
  • D-Pharm
  • F. Hoffmann-La Roche
  • Grupo Ferrer Internacional
  • GW Pharmaceuticals
  • Insero Health
  • INSYS Therapeutics
  • Janssen Pharmaceuticals
  • Ligand Pharmaceuticals
  • H. Lundbeck
  • MarcoPolo Pharmaceuticals
  • Marinus Pharmaceuticals
  • Meda
  • Neurelis
  • Nobelpharma
  • Novartis
  • Orphelia Pharma
  • SAGE Therapeutics
  • SciFlour
  • Sedor Pharmaceuticals
  • Shire
  • SK Biopharmaceuticals
  • Sun Pharmaceutical
  • Sunovion Pharmaceuticals (US)
  • Supernus Pharmaceuticals
  • Takeda
  • Turing Pharmaceuticals
  • Upsher-Smith
  • Valeant Pharmaceutical
  • Zogenix

Market driver

  • Tentative approval of late-stage pipeline molecules
  • For a full, detailed list, view our report

Market challenge

  • Social stigma associated with epilepsy
  • For a full, detailed list, view our report

Market trend

  • Reformulation of marketed drugs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Epilepsy: An overview

PART 05: Pipeline analysis

PART 06: Key buying criteria for anti-epileptic drugs

PART 07: Market landscape

  • Market overview
  • Five forces analysis

PART 08: Market segmentation by generation of drugs

  • First-generation anti-epileptic drugs
  • Second-generation anti-epileptic drugs
  • Third-generation anti-epileptic drugs

PART 09: Market segmentation by spectrum of activity

  • Narrow-spectrum anti-epileptic drugs
  • Broad-spectrum anti-epileptic drugs

PART 10: Market segmentation by type of seizures

  • Partial onset seizures
  • Generalized seizures

PART 11: Geographical segmentation

  • Global epilepsy drugs market by geography 2016-2020
  • Epilepsy drugs market in Americas
  • Epilepsy drugs market in US
  • Epilepsy drugs market in EMEA
  • Epilepsy drugs market in APAC
  • Epilepsy drugs market in Japan
  • Epilepsy drugs market in Australia
  • Epilepsy drugs market in China
  • Epilepsy drugs market in India

PART 12: Market drivers

  • Tentative approval of late-stage pipeline molecules
  • Special regulatory designations
  • Development of novel therapeutics using innovative technologies

PART 13: Impact of drivers

PART 14: Market challenges

  • Social stigma associated with epilepsy
  • Growing use of seizure management devices is a threat to drug therapies
  • Gradual decrease in incentives/investment by vendors for new drug development

PART 15: Impact of drivers and challenges

PART 16: Market trends

  • Development of devices and smartphone apps to detect seizures and track medications
  • Reformulation of marketed drugs
  • Increased uptake of new-generation drugs

PART 17: Vendor landscape

  • Competitive scenario
  • Key news

PART 18: Key vendor analysis

  • Eisai
  • GSK
  • Pfizer
  • UCB
  • Other prominent vendors

PART 19: Appendix

  • List of abbreviations

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Pipeline portfolio: Epilepsy drugs
  • Exhibit 03: Percentage share of pipeline molecules for global epilepsy drugs market
  • Exhibit 04: Key buying criteria for anti-epileptic drugs
  • Exhibit 05: Global epilepsy drugs market snapshot: Developed and emerging markets 2015
  • Exhibit 06: Global epilepsy drugs market 2015-2020 ($ billions)
  • Exhibit 07: A few research studies targeting cause of epilepsy
  • Exhibit 08: Segmentation of marketed anti-epileptic drugs based on mechanism of action
  • Exhibit 09: Five forces analysis
  • Exhibit 10: Timeline of development of anti-epileptic drugs
  • Exhibit 11: Segmentation of global anti-epileptic drugs market based on generation of drugs 2015
  • Exhibit 12: Opportunity analysis of global epilepsy drugs market by generation of drugs
  • Exhibit 13: Segmentation of global epilepsy drugs market by the spectrum of activity of drugs 2015
  • Exhibit 14: Segmentation of global epilepsy drugs market based on type of seizures
  • Exhibit 15: Global epilepsy drugs market by geography 2015-2020
  • Exhibit 16: Global epilepsy drugs market by geography 2015 and 2020
  • Exhibit 17: Global epilepsy drugs market by geography 2015-2020 ($ billions)
  • Exhibit 18: Epilepsy drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 19: Epilepsy drugs market in Americas by geography 2015
  • Exhibit 20: Comparison of US healthcare system: Before and after reforms
  • Exhibit 21: Epilepsy drugs market in US 2015-2020 ($ billions)
  • Exhibit 22: Epilepsy drugs market in EMEA by geography 2015
  • Exhibit 23: Epilepsy drugs market in EMEA 2015-2020 ($ billions)
  • Exhibit 24: Epilepsy drugs market in APAC 2015-2020 ($ billions)
  • Exhibit 25: Epilepsy drugs market in APAC by geography 2015
  • Exhibit 26: Epilepsy drugs market in Japan 2015-2020 ($ millions)
  • Exhibit 27: Epilepsy drugs market in Australia 2015-2020 ($ millions)
  • Exhibit 28: Epilepsy drugs market in China 2015-2020 ($ millions)
  • Exhibit 29: Epilepsy drugs market in India 2015-2020 ($ millions)
  • Exhibit 30: Impact of drivers
  • Exhibit 31: Impact of drivers and challenges
  • Exhibit 32: Position of key vendors in global epilepsy drugs market 2015
  • Exhibit 33: Geographical presence of key vendors
  • Exhibit 34: Company portfolio analysis in global epilepsy drugs market 2016-2020
  • Exhibit 35: Eisai: YoY revenue and growth rate of Fycompa (Americas and EMEA) 2013-2015 ($ millions)
  • Exhibit 36: Eisai: YoY revenue and growth rate of Zonegran (EMEA) 2013-2015 ($ millions)
  • Exhibit 37: Eisai: YoY revenue and growth rate of Banzel (Americas and EMEA) 2013-2015 ($ millions)
  • Exhibit 38: Eisai: YoY revenue and growth rate of Zebinix (EMEA) 2013-2015 ($ millions)
  • Exhibit 39: Eisai: Metrics analysis
  • Exhibit 40: GSK: YoY revenue and growth rate of Lamictal 2013-2015 ($ millions)
  • Exhibit 41: GSK: Metrics analysis
  • Exhibit 42: Pfizer: YoY revenue and growth rate of Lyrica 2013-2015 ($ billions)
  • Exhibit 43: Pfizer: YoY revenue and growth rate of Lyrica 2013-2015 ($ billions)
  • Exhibit 44: Pfizer: Metrics analysis
  • Exhibit 45: UCB: YoY revenue and growth rate of Keppra 2013-2015 ($ millions)
  • Exhibit 46: UCB: Geographical segmentation of Keppra by revenue 2015
  • Exhibit 47: UCB: YoY revenue and growth rate of Vimpat 2013-2015 ($ millions)
  • Exhibit 48: UCB: Geographical segmentation of Keppra by revenue 2015
  • Exhibit 49: UCB: Metrics analysis
Back to Top